Session 4: Immunology of HIV Persistence

8h00-10h00

Michaela Muller-Trutwin, Institut Pasteur - Paris, FRA

Understanding the landscape of lymph node HIV reservoirs during ART through single cell analysis

Michael BETTS - Philadelphia, USA

Tissue resident memory programs of intestinal CD4+ and CD8+ T cells facilitate HIV-1 persistence

Yulong WEI - New Haven, USA

Secondary cytotoxicity of memory CD8+ T cells targeting autologous HIV during treated chronic infection is associated with suppression of provirus and of recrudescent viremia

David COLLINS – Cambridge, USA

HIV infection induces T cell quiescence, leading to proviral latency

Saba VALADKHAN - Ohio, USA

Molecular Drivers of HIV-Induced Immune Modulation and CD8+ T Cell Dysfunction in Lymph Node Follicles during ART-Suppressed Subtype C Infection

Zaza NDHLOVU - Durban, ZAF

Control of HIV infection is associated with enhanced CD8 T cell functionality during consecutive analytical treatment interruptions

Gabriel DUETTE - Sydney, AUS

Transcriptomic profile of gut T follicular helper cells during persistent HIV infection

Francesca COSSARINI - New York, USA

Session 5: In Vitro and Animal Model Studies of HIV Persistence

10h30-12h30

J. Victor Garcia-Martinez, The University of Alabama, Birmingham, USA

Targeting Anti-apoptotic Molecules to Eliminate the SIV Reservoir

Mirko PAIARDINI - Atlanta, USA

Plasma SIVmac239M clonotypes in rebound viremia correspond to those induced by AZD5582 during ART

Ann CHAHROUDI - Atlanta, USA

Well-seeded reservoirs in gut are associated with tertiary lymphoid organs and stress response activation

Ramon LORENZO-REDONDO - Chicago, USA

Macrophage-tropic TF SHIV D infected NHP model of reservoir persistence, decay and pathogenesis on suppressive anti-retroviral therapy

Suvadip MALLICK - Philadelphia, USA

Targeting Wnt/?-catenin signaling pathway during latency reversal in ART-suppressed SIV-infected rhesus macaques

Maud MAVIGNER - Atlanta, USA

HIV-Tocky system in primary CD4+T cells joined with transcriptomic and epigenomic analysis to discover mechanism involves in the establishment of latency during acute infection

Wajihah SAKHOR - Kumamoto, JAP

Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

Yuntao WU - Manassas, USA

Session 6: Cell & Gene Therapies

14h00-16h00

Priti Kumar, Yale School of Medicine, New Haven, USA

Cell and gene therapy for sickle cell disease, insights into HIV gene therapy

John TISDALE - Bethesda, USA

Durable Viral Load Remission in SHIV-infected Macaques after Vectored Delivery of Monoclonal Antibodies

Jose MARTINEZ-NAVIO - Miami, USA

Multivalent CAR T Cell Therapy Shows Superior Potency in Controlling HIV Escape and Replication in BLT Humanized Mice

Federica SEVERI - Philadelphia, USA

AAV Delivery of the CCR5-blocking monoclonal antibody Leronlimab yields long-term expression and ART-free remission from SHIV viremia

Helen WU - Beaverton, USA

Overcoming immune responses directed toward AAV-delivered bNAbs

Michael KUIPA - Atlanta, USA

A single-infusion of CCR5 modified stem-like CD4 T cells to limit HIV/SIV persistence during ART and promote control of viremia upon ATI

Ashish SHARMA, Atlanta, USA

CAR/CCR9 T cell immunotherapy shows promise in localization of SIV-specific CAR T cells to the gastrointestinal tract of rhesus macaques

Pam SKINNER, Minneapolis - USA

Highlighed Short talks of interest II

17h00-18h00

Ann Chahroudi, Emory University - Atlanta, USA
Mary Kearney, National Institutes of Health - Frederick, USA

Distinct features of HIV persistence in children

Katherine LUZURIAGA - Worcester, USA

A Novel HIV-1 Immune Evasion Strategy: How Softer HIV-1 Infected cells Preferentially Resist Cytotoxic T Lymphocytes (CTLs)

Louise LEYRE - New York, USA

Models and correlates of intact and defective HIV DNA decay in Kenyan children over 8 years of ART

Daniel REEVES - Seattle, USA

Targeting Myeloid Reservoirs Harboring Replication-Competent HIV

Jin WANG - Houston, USA

Bach2 controls seeding of HIV reservoirs in memory CD4+ T cells

Liang SHAN - St. Louis, USA

Satellite Workshop - Translating Science

13h00-15h00

A Training Workshop to Support Communicating Cure Science

Jessica Salzwedel, New York - USA

A Training Workshop to Support Communicating Cure Science

Mike Franke (The Düsseldorf Patient), Velen - GER

Satellite Workshop - Research outcomes from NIMH funded StudiesLeveraging Host Cellular Pathways for Targeting HIV CNS/Myeloid Reservoirs

15h30-17h30

Co-Chairs: Kiera Clayton, University of Massachusetts, Worcester, MA, USA
Mario Stevenson, University of Miami, Miami, FL, USA

Welcome Remarks and Meeting Goals

Jeymohan Joseph, NIMH, Rockville,MD, USA

Metabolic strategies to eliminate CNS Myeloid Viral Reservoirs

Eliseo Eugenin, University of Texas, Galveston, TX, USA

Strategies for Depletion of HIV reservoir by activation of ISR Signaling

Guochun Jiang, University of North Carolina, Chapel Hill, NC, USA

Targeting HIV Myeloid Reservoirs in the CNS by IAP and TREM1 Inhibition

Grant Campbell, University of South Dakota, Vermillion, SD, USA

Targeting the HIV-1 Reservoir in Myeloid Cells using the SECH approach

Jin Wang, Methodist Hospital Research Institute, Houston, TX, USA

Modulation of HIV reservoirdynamics in brain pericytes

Michal Toborek, University of Miami School of Medicine, Miami, FL, USA

Repurposing BCL-2 and Jak 1/2 inhibitors for targeting myeloid reservoirs

Boghuma Kabisen Titanji, Emory University, Atlanta, GA, USA

Research Gaps and Future Research Areas Discussion

Kiera Clayton, University of Massachusetts, Worcester, MA, USAMario Stevenson, University of Miami, Miami, FL, USA

OPENING SESSION

18h30-19h30

Welcoming remarks by the Steering Committee

Ann CHAHROUDI - Georgia, United States
Mary KEARNY - MD, USA
David MARGOLIS - Chapel Hill, USA
Karl SALZWEDEL - Bethesda, USA
Mario STEVENSON - Miami, USA

Overall cure landscape from the NIH perspective

Carl Dieffenbach, National Institute of Allergy and Infectious Diseases, Aids Division, Bethesda, USA

Community voice: living on ART and Why a cure is necessary

Antoinette Jones, Dandelion, INC., Atlanta, USA

Session 1: Basic Science of HIV Persistence

8h00-10h00

Una O’Doherty - Emory University School of Medicine - Atlanta, USA

Proviral gene expression and quantitation of the latent HIV-1 reservoir

Tokameh MAHMOUDI - Rotterdam, NED

Longitudinal analysis in early treated individuals reveals alteration in the HIV-1 integration site landscape and composition of the inducible reservoir

Tine STRUYVE - Ghent, BEL

Blood and tissue HIV-1 reservoirs display cellular plasticity and lack of compartmentalization in virally suppressed people

Marion PARDONS - Ghent, BEL

Persistence of HIV genomes in bacteria-specific CD4+ T cells during ART

Armando ESPINOSA ORTIZ - Montréal, CAN

Identification of the cellular transcription factor KLF16 (Krüppel-like factor 16) as a new HIV-1 silencing factor

Maryam BENDOUMOU - Brussels, BEL

Intact Proviruses Persist in Expressed Genes in People with HIV-1 on Long-term ART

Sean PATRO - Frederick, USA

HIV-1 Antisense Transcripts are frequent in FOXP3-negative Treg-like cells expressing markers of persistence in vivo during acute HIV-1 infection

Matthew HALE - Bethesda, USA

Session 2: Virology of HIV Persistence

10h30-12h30

Monique Nijhuis - University Medical Center Utrecht, NED

Persistence of clonally expanded proviruses

Joel BLANKSON - Baltimore, USA

Lenacapavir impairs gag proteins expression by HIV-infected cells

Clayton FAUA - Strasbourg, FRA

Role of HIV integration site on clonal expansion of infected cells and maintenance of latency in vivo

Virender PAL - New York, USA

Detection of HIV-1 antisense transcripts in donor samples before and during ART

Adam CAPOFERRI - Frederick, USA

Selective export of HIV mRNAs is regulated by compartmentalized interactions with Sam68, PTB and m6A RNA methylation in reactivated latently infected T-cells

Fredrick KIZITO - University Heights, USA

Propagation of HIV reservoir clones reveals functional heterogeneity, suggesting diverse mechanisms of persistence

Isabella FERREIRA - New York, USA

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV

Alexander PASTERNAK - Amsterdam, Netherlands

Session 3: Drug Discovery & Development, Pharmacology, Novel approaches

14h00-16h00

Devi SenGupta - Gilead, Foster City, USA

Targeted Activator of Cell Kill (TACK)

Paul ZUCK - West Point, USA

Exploring novel HIV Tat inhibitors

Sonia JABLONSKI - Florida, USA

New PKC Modulator Latency Reversing Agents for depleting persistent HIV reservoirs

Matthew MARSDEN - Irvine, USA

RasGRP1 agonists induce cyclin T1 translation to reverse HIV-1 latency in primary CD4+ T cells

Uri MBONYE - Cleveland, USA

Unbiased Genome-Wide CRISPR Screens in Primary Human CD4+ T Cells Identify Novel Proviral and Anti-viral HIV Host Factors

Ujjwal RATHORE- San Francisco, USA

Monovalent SMAC mimetics enhance proliferation of HIV-specific CD8 T cells

Kiho TANAKA - Melbourne, USA

Clinical and virologic outcomes of an art interruption in treated controllers and non-controllers

Michael PELUSO - San Francisco, USA

Highlighed Short talks of interest I

16h00-17h00

David Margolis University of North Carolina, Chapel Hill, USA
Mario Stevenson - University of Miami, Leonard M. Miller School of Medicine, Miami, USA

Block and Lock strategy for HIV cure

Susana VALENTE - Jupiter, USA

Single cell transcriptomic characterization of the gastrointestinal HIV reservoir

Edward BROWNE - Chapel Hill, USA

Characterization of the molecular mechanisms involved in the CD8+ T cell-mediated non-cytolytic silencing of HIV-1 transcription

Antoine DUTILLEUL - Brussels, BEL

Venetoclax decreases intact proviral DNA frequency in SIV-infected, ART-suppressed Rhesus Macaques

Sydney BERGSTRESSER - Atlanta, BEL

Persistent HIV-1 unintegrated linear DNA can integrate and lead to viral replication after integrase inhibitor treatment removal

Matthieu MAISCH - Paris, FRA

Session 7: Human Studies

8h00-10h00

Nancie Archin, UNC Chapel Hill, USA

Diversity in clinical studies: identifying and overcoming barriers

Esper KALLAS - São Paulo, BRA

Safety and PD-1 receptor occupancy with low dose Nivolumab in adults living with HIV on antiretroviral therapy: NIVO-LD

James MCMAHON - Melbourne, AUS

Peptide-induced apoptosis of latently infected cells and reduction of the HIV reservoir in people living with HIV: preliminary results of a clinical trial

Ricardo SOBHIE DIAZ - São Paulo, BRA

Profound reduction of HIV-1 reservoir cells over three decades of antiretroviral therapy started in early infancy

Katherine RUIZ-DE-LUZURIAGA - Worcester, USA

Anatomic distribution of HIV-infected clones in tissues after long-term antiretroviral therapy

Frank MALDARELLI - Frederick, USA

Postmortem analyses of the central nervous system in individuals with HIV demonstrate that infection of microglia contributes to inflammatory pathways despite viral suppression.

Marieke NÜHN - Utrecht, NED

The Tuberculosis Associated Microenvironment Reduces CD8+ T-Cell Control of HIV at the Site of the Coinfection

Samantha CRONIN - Sydney, AUS

Session 8: Antibody & Immune based Therapies

10h30-12h30

Marina Caskey, Rockefeller University, USA

Development of multispecific antibodies for HIV

John MASCOLA - Weston, USA

Short-term Combination Immunotherapy with bNAbs and CCR5 Blockade Mediates ART-Free Viral Control in Infant Rhesus Macaques

Gabriela WEBB - Portland, USA

Early intervention with an indoline CD4-mimetic compound that sensitizes HIV-1-infected cells to ADCC favors post-treatment HIV control in humanized mice

Li ZHU - New Haven, USA

Epitope-Driven Effector Functions of Broadly Neutralizing Antibodies Across Diverse HIV Isolates: Insights for Next-Generation Therapeutics

Chia Jung LI - Massachusetts, USA

IL-15/IL-15RA therapy enhances control of viral rebound in SIV-infected macaques

Sakthivel GOVINDARAJ - Atlanta, USA

Changes in the composition of HIV-1 reservoir of PWH on ART and dasatinib

Mario MANZANARES - Madrid, USA

Increased HIV-1 proviral reactivation and reservoir size in people with HIV on anticancer treatment

Laura PEREZ-BLAZQUEZ - Madrid, USA

Closing Remarks

12h30-13h00